IHE vs IXJ: 39.7% vs 10% 1-Year Returns in ETFs Comparison
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowThe iShares U.S. Pharmaceuticals ETF (IHE) has posted a 1-year return of 39.70% as of May 20, 2026, while the iShares Global Healthcare ETF (IXJ) reported a return of 10.00%. Both funds have similar expense ratios, with IHE at 0.38% and IXJ at 0.40%. IHE's assets under management (AUM) stand at $883.6 million, compared to IXJ's $3.6 billion. Additionally, IHE has a higher dividend yield of 1.70% versus IXJ's 1.50%, indicating potential advantages for investors favoring domestic pharmaceutical exposure.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Eli Lilly (LLY) plans nearly $4 billion vaccine acquisitions
- Eli Lilly (LLY) Stock Rating Reiterated Amid Gene Therapy Progress
- Eli Lilly (LLY) next-gen obesity drug achieves 28.3% weight loss
- Eli Lilly (LLY) Price Target Raised to $1,400 Following Q1 Results
- Novo Nordisk (NVO) high-dose Wegovy shows 27.7% weight loss
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
